Investing.com - Biomerieux reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biomerieux announced earnings per share of €2.33 on revenue of €729.6M. Analysts polled by Investing.com anticipated EPS of €2.09 on revenue of €774M.
Biomerieux shares are down 6% from the beginning of the year and are trading at €108.00 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 18.57% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings missed by EssilorLuxottica on August 20, who reported EPS of €1.93 on revenue of €4.71B, compared to forecasts EPS of €2.31 on revenue of €4.59B.
Valneva had matched expectations on August 10 with second quarter EPS of €-0.61 on revenue of €24.29M, compared to forecast for EPS of €-0.61 on revenue of €24.3M (NYSE:MMM).
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar